INTRODUCTION

STs
1 are a family of homologous peptides produced by bacteria that cause diarrhea in travelers, under-developed countries, and farm animals (1) (2) (3) (4) . ST induces intestinal secretion by binding to GC-C, a single transmembrane protein that is expressed exclusively in the brush border of intestinal epithelial cells from the duodenum to the rectum in adult humans (5) (6) (7) (8) (9) (10) . Toxin interaction with the extracellular domain activates the cytoplasmic catalytic domain of GC-C inducing accumulation of [cGMP] i (11) . This cyclic nucleotide activates PKG II, which phosphorylates the cystic fibrosis transmembrane conductance regulator increasing chloride transport, and inhibits electroneutral sodium absorption, resulting in fluid and electrolyte secretion in the intestine and diarrhea (11) (12) (13) .
STs are an example of molecular mimicry wherein bacteria have developed an evolutionarily advantageous strategy that exploits mechanisms regulating normal intestinal physiology. STs are members of a larger family of peptides that include guanylin and uroguanylin, GC-C agonists produced endogenously in mammalian gut (14) (15) (16) (17) . These peptides share sequence homology, have a tertiary structure stabilized by intrachain disulfide bonds, and exert their (patho)physiological effects by binding to GC-C and inducing cGMP accumulation.
Uroguanylin, which is highly expressed in stomach, duodenum and jejunum, is 100-fold more potent than guanylin at acidic pH (18, 19) . In contrast, guanylin is more abundant in ileum and colon and is 4-fold more potent than uroguanylin at a pH of 8.0 (18, 19) . These endogenous GC-C agonists may regulate physiological processes in distinct regions of the intestine, modulated by local pH.
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Although guanylin-like peptides and GC-C appear to regulate fluid and electrolyte balance in intestine, the precise role of this receptor in normal intestinal physiology remains undefined. GC-C exhibits broad phylogenetic expression, suggesting the existence of an evolutionary pressure mediating its conservation (20, 21) . In intestine, GC-C is expressed along a crypt-to-villus gradient with the greatest expression in the mid-villus where enterocytes transition from proliferation to differentiation, suggesting that GC-C may play a role in regulating that transition (22, 23) . Also, expression of GC-C is highly conserved, whereas that of guanylin is significantly reduced, in proliferating colorectal cancer cells and tumors (10, (24) (25) (26) (27) . In addition, oral uroguanylin reduced the formation of polyps in the Min/+ mouse model of colon cancer (27) .
Taken together, these observations suggest an association between GC-C and the regulation of enterocyte proliferation.
In this study, regulation of human colon cancer cell proliferation by GC-C was examined in vitro. ST and uroguanylin inhibited the proliferation of human colon cancer cells by activating GC-C and stimulating accumulation of cGMP. Inhibition of intestinal cell proliferation by GC-C agonists reflected prolongation of the cell cycle in the absence of cell death. Statistics. All determinations were performed at least in duplicate, experiments were performed at least in triplicate, and data are expressed as mean ± SEM. Data were analyzed employing the paired two-tailed Student's t-test, and significance was assumed at p<0.05. (Fig. 4A ). There were no differences in the percentages of apoptotic cells in cultures incubated with ST or uroguanylin compared to PBS (Fig. 4B) . A recent report suggested that uroguanylin induced apoptosis in T84 cells (27) . However, there were no differences in DNA fragmentation in T84 cells processed as homologous to guanylin and uroguanylin elaborated in mammalian intestine (14) (15) (16) (17) . Although these peptides are endogenous GC-C agonists, their precise role in intestinal physiology has remained undefined. One hypothesis suggests a role for these peptides in the paracrine and autocrine regulation of fluid and electrolyte homeostasis in the intestine. Also, these peptides are expressed in extra-intestinal sites, including the kidney, suggesting that they may comprise one limb of an endocrine feedback loop that integrates the intestine into mechanisms regulating volume homeostasis (18, 19) . This function for GC-C is analogous to that for GC-A and GC-B and their agonists, the natriuretic peptides, which regulate fluid and electrolyte secretion in the kidney and play a central role in volume homeostasis (11) .
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Also, GC-C may regulate processes other than fluid and electrolyte secretion in the intestine. Of significance, natriuretic peptides inhibit proliferation in human cell lines by interacting with guanylyl cyclase receptors and inducing accumulation of cGMP (35) (36) (37) . Similarly, cGMP inhibits proliferation in several cell lines (38) (39) (40) (41) . Cyclic GMP delays the G 1 /S transition in human vascular smooth muscle cells (42) . In addition, exisulind, which inhibits cGMP-specific PDE, induces apoptosis in human colon cancer cells in vitro (43, 44) . Furthermore, recent studies suggest that uroguanylin induces apoptosis in T84 and Caco2 human colon cancer cells (27) .
Thus, in some cell systems, including human intestine, guanylyl cyclases and cGMP may regulate cell proliferation and/or apoptosis (42, 45, 46) . without specific effects on a particular phase of that cycle, remain undefined, although this phenomenon has been observed previously (48) .
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In conclusion, agonist activation of GC-C regulates the proliferation of colon carcinoma cells by slowing progression through the cell cycle without inducing cell death. These data suggest that GC-C and its endogenous agonists, guanylin and uroguanylin, may play a role in regulating the transition between intestinal stem cell proliferation and their differentiation into mature enterocytes (52) . Additionally, they support the suggestion that GC-C agonists may represent novel cytostatic agents for the prevention and treatment of colorectal cancer. 
